158 related articles for article (PubMed ID: 24291818)
21. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
22. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
24. Fragment-based ligand design of novel potent inhibitors of tankyrases.
Larsson EA; Jansson A; Ng FM; Then SW; Panicker R; Liu B; Sangthongpitag K; Pendharkar V; Tai SJ; Hill J; Dan C; Ho SY; Cheong WW; Poulsen A; Blanchard S; Lin GR; Alam J; Keller TH; Nordlund P
J Med Chem; 2013 Jun; 56(11):4497-508. PubMed ID: 23672613
[TBL] [Abstract][Full Text] [Related]
25. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease.
Guettler S; LaRose J; Petsalaki E; Gish G; Scotter A; Pawson T; Rottapel R; Sicheri F
Cell; 2011 Dec; 147(6):1340-54. PubMed ID: 22153077
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.
Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H
J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110
[TBL] [Abstract][Full Text] [Related]
27. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
28. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
29. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
[TBL] [Abstract][Full Text] [Related]
30. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
Voronkov A; Holsworth DD; Waaler J; Wilson SR; Ekblad B; Perdreau-Dahl H; Dinh H; Drewes G; Hopf C; Morth JP; Krauss S
J Med Chem; 2013 Apr; 56(7):3012-23. PubMed ID: 23473363
[TBL] [Abstract][Full Text] [Related]
31. Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
Eisemann T; Langelier MF; Pascal JM
J Biol Chem; 2019 Oct; 294(40):14574-14590. PubMed ID: 31375564
[TBL] [Abstract][Full Text] [Related]
32. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities.
Zamudio-Martinez E; Herrera-Campos AB; Muñoz A; Rodríguez-Vargas JM; Oliver FJ
J Exp Clin Cancer Res; 2021 Apr; 40(1):144. PubMed ID: 33910596
[TBL] [Abstract][Full Text] [Related]
33. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.
Xu W; Lau YH; Fischer G; Tan YS; Chattopadhyay A; de la Roche M; Hyvönen M; Verma C; Spring DR; Itzhaki LS
J Am Chem Soc; 2017 Feb; 139(6):2245-2256. PubMed ID: 28084734
[TBL] [Abstract][Full Text] [Related]
34. Regulation of tankyrase activity by a catalytic domain dimer interface.
Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
[TBL] [Abstract][Full Text] [Related]
35. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
Mariotti L; Templeton CM; Ranes M; Paracuellos P; Cronin N; Beuron F; Morris E; Guettler S
Mol Cell; 2016 Aug; 63(3):498-513. PubMed ID: 27494558
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment.
Morrone S; Cheng Z; Moon RT; Cong F; Xu W
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1500-5. PubMed ID: 22307604
[TBL] [Abstract][Full Text] [Related]
37. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure of a tankyrase 1-telomere repeat factor 1 complex.
Li B; Qiao R; Wang Z; Zhou W; Li X; Xu W; Rao Z
Acta Crystallogr F Struct Biol Commun; 2016 Apr; 72(Pt 4):320-7. PubMed ID: 27050267
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of isoquinolin-1(2
Yao H; Wang Y; Jiangwen M; Peng Y; Wang Z
Pharmazie; 2021 Apr; 76(4):132-137. PubMed ID: 33849696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]